20:52 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

Oral Debio 1450: Ph II data

Top-line data from 284 evaluable patients with ABSSSIs due to Staphylococcus , including methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA), in the microbiological intent-to-treat (mITT) population of a double-blind, U.S. Phase II trial showed...
20:49 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

IV Debio 1450: Ph II data

Top-line data from 284 evaluable patients with ABSSSIs due to Staphylococcus, including methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA), in the microbiological intent-to-treat (mITT) population of a double-blind, U.S. Phase II trial showed that...
23:59 , Jan 10, 2017 |  BC Extra  |  Clinical News

Debiopharm antibiotic passes Phase II ABSSSI test

Debiopharm Group (Lausanne, Switzerland) said antibiotic candidate Debio 1450 met the primary endpoint of non-inferiority to vancomycin plus linezolid across all tested Staphylococcus species in a Phase II trial to treat acute bacterial skin and...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
07:00 , Mar 21, 2016 |  BioCentury  |  Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
07:00 , Oct 29, 2015 |  BC Innovations  |  Product R&D

Qureing antibiotic resistance

QureTech Bio AB is targeting chlamydia and tuberculosis with compounds that disable, rather than kill, pathogens to circumvent antibiotic resistance. By targeting the organisms' virulence factors, the company hopes to spare the host flora and...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Debio 1450: Phase II started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase II trial to compare 2 doses of IV Debio 1450 given 12 hours apart followed by twice-daily oral Debio 1450 vs. 2 doses of IV vancomycin given 12...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Debio 1450: Phase II started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase II trial to compare 2 doses of IV Debio 1450 given 12 hours apart followed by twice-daily oral Debio 1450 vs. 2 doses of IV vancomycin given 12...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Debio 1450 regulatory update

Debiopharm said FDA granted Qualified Infectious Disease Product (QIDP) designation to Debio 1450 to treat acute bacterial skin and skin structure infections (ABSSSI). The small molecule prodrug inhibitor of the bacterial fabI enoyl-(acyl carrier protein)...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

oral Debio 1450: Phase I started

Debiopharm began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of oral Debio 1450 in up to 48 healthy subjects. An IV formulation of the product is in Phase I testing. Debiopharm...